Endocrine Abstracts

Introduction: Type 2 diabetes represents an important health problem and is designated by a progressive course. Since the vast majority of type 2 diabetic patients are overweight, there is a need not only to avoid weight gain but to lower body weight. Therefore, the usage of drugs that have the potential to lower body weight (GLP1 RA and SGLT2 -inhibitors) should with metformin be preferred initial therapy in the obese and overweight type 2 diabetic patients.<p class="abst...

Introduction: Maternally-inherited diabetes with deafness (MIDD) is a rare form of monogenetic diabetes caused by a point mutation in mitochondrial DNA at a position 3243A>G. The syndrome is characterised by diabetes and sensoneural hearing impairment. Additional clinical features include short stature, cardiomyopathy, myopathy, renal disease, macular dystrophy, and gastrointestinal disease. The majority of patients usually require insulin therapy within 2 years and metfor...

Introduction: Topical wound oxygen therapy (TWO2) is therapeutic modality that delivers humidified pressurised O2 directly to the specific body part to achieve tissue penetration and increased O2 levels to the open ischaemia wound. O2 is vital in the synthesis of collagen, enhancement of fibroblasts, angiogenesis, leukocyte function, energy metabolism, and the inhibition of mycrobial growth. TWO2 therapy has showed effecti...

Introduction: Many type 2 diabetes patients continue to have poor glycaemic control and would benefit from insulin therapy. One of the risks that hinders insulin use is hypoglycemia. Optimal insulin therapy should therefore minimize the risk of hypoglycemia while improving glycemic control. Newer insulin preparations degludec and glargin 300 units/ml show more even and prolonged pharmacokinetic profile, enabling an evenly distributed daytime glucose-lowering effect with high r...